Literature DB >> 1829024

Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide.

M Pollard1, P H Luckert, M B Sporn.   

Abstract

We report for the first time that a synthetic retinoid, N-(4-hydroxyphenyl)retinamide, can prevent the development of both primary and metastatic tumors in an animal model of metastasizing primary prostate cancer. Prostatic adenocarcinomas were induced in high incidence in Lobund-Wistar rats by initiation with methylnitrosourea i.v. and promotion with testosterone. Feeding of N-(4-hydroxyphenyl)retinamide to these rats during the latency period markedly diminished the final incidence of both primary and metastatic prostate carcinomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829024

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

2.  Selective apoptosis induction by the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide is achieved by modulating mitochondrial bioenergetics in premalignant and malignant human prostate epithelial cells.

Authors:  Numsen Hail; Ping Chen; Jadwiga J Kepa
Journal:  Apoptosis       Date:  2009-07       Impact factor: 4.677

Review 3.  Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.

Authors:  Christina Voelkel-Johnson; James S Norris; Shai White-Gilbertson
Journal:  Adv Cancer Res       Date:  2018-06-20       Impact factor: 6.242

4.  Androgen receptor expression in primary prostate cancers of Lobund-Wistar rats and in tumor-derived cell lines.

Authors:  J M Bentel; M A Pickering; M Pollard; J A Clements; W D Tilley
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

5.  Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression.

Authors:  M R Shaker; G Yang; T L Timme; S H Park; D Kadmon; C Ren; X Ji; H M Lee; I Sehgal; M Anzano; M B Sporn; T C Thompson
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).

Authors:  M M Webber; D Bello-DeOcampo; S Quader; N D Deocampo; W S Metcalfe; R M Sharp
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

7.  Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer.

Authors:  Rainer Kuefer; Felicitas Genze; Waltraud Zugmaier; Richard E Hautmann; Ludwig Rinnab; Juergen E Gschwend; Marina Angelmeier; Aidee Estrada; Berthold Buechele
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

8.  Chemoprevention strategies in the prostate: an overview.

Authors:  Gary J Kelloff; Howard R Higley; Michael K Brawer; M Scott Lucia; Caroline C Sigman; E David Crawford
Journal:  Rev Urol       Date:  2002

9.  The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability.

Authors:  Roberto Benelli; Stefano Monteghirfo; Roberta Venè; Francesca Tosetti; Nicoletta Ferrari
Journal:  Mol Cancer       Date:  2010-06-10       Impact factor: 27.401

Review 10.  Tomatoes, lycopene and prostate cancer: a clinician's guide for counseling those at risk for prostate cancer.

Authors:  Kamal S Pohar; Michael C Gong; Robert Bahnson; Elizabeth C Miller; Steven K Clinton
Journal:  World J Urol       Date:  2003-03-22       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.